Results 1 to 10 of about 14,603 (156)

Risks from self-medicating with psychedelic drugs. [PDF]

World Psychiatry
Black JC.
europepmc   +3 more sources

Embodied Transformation: Psychedelic Therapy Through the Lens of Merleau-Ponty's Phenomenology. [PDF]

Integr Psychol Behav Sci
Ritschel Z, Wagoner B.
europepmc   +3 more sources

High ventilation breathwork as a non-pharmacological model for inducing psychedelic-like states: expert evaluations of therapeutic potential and risk. [PDF]

Npj Ment Health Res
Lueken U, Dziobek I, Havenith MN, Schild M, Daedelow LS.   +4 more
europepmc   +3 more sources

Case analysis of long-term negative psychological responses to psychedelics

Scientific Reports, 2023
Recent controversies have arisen regarding claims of uncritical positive regard and hype surrounding psychedelic drugs and their therapeutic potential. Criticisms have included that study designs and reporting styles bias positive over negative outcomes.
Rebecka Bremler, Nancy Katati, Parvinder Shergill, David Erritzoe, Robin L. Carhart-Harris   +4 more
doaj   +1 more source

Effects of psilocybin versus escitalopram on rumination and thought suppression in depression

BJPsych Open, 2022
Background Major depressive disorder is often associated with maladaptive coping strategies, including rumination and thought suppression. Aims To assess the comparative effect of the selective serotonin reuptake inhibitor escitalopram, and the ...
Tommaso Barba, Sarah Buehler, Hannes Kettner, Caterina Radu, Bruna Giribaldi Cunha, David J. Nutt, David Erritzoe, Leor Roseman, Robin Carhart-Harris   +8 more
doaj   +1 more source

Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing

Scientific Reports, 2021
Psychedelic microdosing describes the ingestion of near-threshold perceptible doses of classic psychedelic substances. Anecdotal reports and observational studies suggest that microdosing may promote positive mood and well-being, but recent placebo ...
L. S. Kaertner, M. B. Steinborn, H. Kettner, M. J. Spriggs, L. Roseman, T. Buchborn, M. Balaet, C. Timmermann, D. Erritzoe, R. L. Carhart-Harris   +9 more
doaj   +1 more source

Lived experience as systems-relevant evidence in psychedelic public health [PDF]

Front Public Health
Dara P.
europepmc   +3 more sources

Effects of Naturalistic Psychedelic Use on Depression, Anxiety, and Well-Being: Associations With Patterns of Use, Reported Harms, and Transformative Mental States

Frontiers in Psychiatry, 2022
Survey-based studies suggest naturalistic psychedelic use provides mental health benefits similar to those observed in clinical trials. The current study sought to confirm these findings in a large group of psychedelic users and to conduct a novel ...
Charles L. Raison, Rakesh Jain, Andrew D. Penn, Steven P. Cole, Saundra Jain   +4 more
doaj   +1 more source

The difference between ‘placebo group’ and ‘placebo control’: a case study in psychedelic microdosing

Scientific Reports, 2023
In medical trials, ‘blinding’ ensures the equal distribution of expectancy effects between treatment arms in theory; however, blinding often fails in practice.
Balázs Szigeti, David Nutt, Robin Carhart-Harris, David Erritzoe   +3 more
doaj   +1 more source

Co-use of MDMA with psilocybin/LSD may buffer against challenging experiences and enhance positive experiences

Scientific Reports, 2023
Psilocybin and lysergic acid diethylamide (LSD) experiences can range from very positive to highly challenging (e.g., fear, grief, and paranoia). These challenging experiences contribute to hesitancy toward psychedelic-assisted psychotherapy among health
Richard J. Zeifman, Hannes Kettner, Broc A. Pagni, Austin Mallard, Daniel E. Roberts, David Erritzoe, Stephen Ross, Robin L. Carhart-Harris   +7 more
doaj   +1 more source